A Tissue Biopsy-based Epigenetic Multiplex PCR Assay for Prostate Cancer Detection

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2012 Jun 8

PMID 22672250

Citations 20

Authors

Leander Van Neste

Joseph Bigley

Adam Toll

Gaetan Otto

James Clark

Paul Delree

Wim Van Criekinge

Jonathan I Epstein

Affiliations

Soon will be listed here.

Abstract

Background: PSA-directed prostate cancer screening leads to a high rate of false positive identifications and an unnecessary biopsy burden. Epigenetic biomarkers have proven useful, exhibiting frequent and abundant inactivation of tumor suppressor genes through such mechanisms. An epigenetic, multiplex PCR test for prostate cancer diagnosis could provide physicians with better tools to help their patients. Biomarkers like GSTP1, APC and RASSF1 have demonstrated involvement with prostate cancer, with the latter two genes playing prominent roles in the field effect. The epigenetic states of these genes can be used to assess the likelihood of cancer presence or absence.

Results: An initial test cohort of 30 prostate cancer-positive samples and 12 cancer-negative samples was used as basis for the development and optimization of an epigenetic multiplex assay based on the GSTP1, APC and RASSF1 genes, using methylation specific PCR (MSP). The effect of prostate needle core biopsy sample volume and age of formalin-fixed paraffin-embedded (FFPE) samples was evaluated on an independent follow-up cohort of 51 cancer-positive patients. Multiplexing affects copy number calculations in a consistent way per assay. Methylation ratios are therefore altered compared to the respective singleplex assays, but the correlation with patient outcome remains equivalent. In addition, tissue-biopsy samples as small as 20 μm can be used to detect methylation in a reliable manner. The age of FFPE-samples does have a negative impact on DNA quality and quantity.

Conclusions: The developed multiplex assay appears functionally similar to individual singleplex assays, with the benefit of lower tissue requirements, lower cost and decreased signal variation. This assay can be applied to small biopsy specimens, down to 20 microns, widening clinical applicability. Increasing the sample volume can compensate the loss of DNA quality and quantity in older samples.

Citing Articles

Detection of differentially methylated CpGs between tumour and adjacent benign cells in diagnostic prostate cancer samples.

FitzGerald L, Jung C, Wong E, Joo J, Bassett J, Dowty J Sci Rep. 2024; 14(1):17877.

PMID: 39095452 PMC: 11297152. DOI: 10.1038/s41598-024-66488-x.

Biomarkers for Prostate Cancer: From Diagnosis to Treatment.

Chen J, Wang P, Liu M, Lyu F, Ma M, Ren X Diagnostics (Basel). 2023; 13(21).

PMID: 37958246 PMC: 10649216. DOI: 10.3390/diagnostics13213350.

Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive Prostate Cancer.

Gupta H, Inoue H, Nakai Y, Nakayama M, Jones T, Hicks J Cancer Prev Res (Phila). 2023; 16(8):449-460.

PMID: 37347938 PMC: 10529302. DOI: 10.1158/1940-6207.CAPR-22-0485.

Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.

Byun Y, Kang H, Piao X, Zheng C, Moon S, Choi Y Prostate Int. 2022; 10(1):1-6.

PMID: 35155300 PMC: 8804185. DOI: 10.1016/j.prnil.2021.11.003.

Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.

Basourakos S, Tzeng M, Lewicki P, Patel K, Al Hussein Al Awamlh B, Venkat S Front Oncol. 2021; 11:676716.

PMID: 34123846 PMC: 8193839. DOI: 10.3389/fonc.2021.676716.

References

Babaian R . Extended field prostate biopsy enhances cancer detection. Urology. 2000; 55(4):453-6. DOI: 10.1016/s0090-4295(00)00469-6. View

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Chou R, Croswell J, Dana T, Bougatsos C, Blazina I, Fu R . Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155(11):762-71. DOI: 10.7326/0003-4819-155-11-201112060-00375. View

Trock B, Brotzman M, Mangold L, Bigley J, Epstein J, McLeod D . Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2011; 110(1):56-62. PMC: 3397791. DOI: 10.1111/j.1464-410X.2011.10718.x. View

Jeronimo C, Henrique R, Hoque M, Mambo E, Ribeiro F, Varzim G . A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004; 10(24):8472-8. DOI: 10.1158/1078-0432.CCR-04-0894. View

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman C . Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000; 163(4):1144-8; discussion 1148-9. View

Baldi P, Brunak S, Chauvin Y, Andersen C, Nielsen H . Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics. 2000; 16(5):412-24. DOI: 10.1093/bioinformatics/16.5.412. View

10.

Smith D, Humphrey P, Catalona W . The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer. 1997; 80(9):1852-6. View

11.

Baylin S, Fearon E, Vogelstein B, De Bustros A, Sharkis S, Burke P . Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood. 1987; 70(2):412-7. View

12.

McGarvey K, Van Neste L, Cope L, Ohm J, Herman J, Van Criekinge W . Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res. 2008; 68(14):5753-9. PMC: 2706536. DOI: 10.1158/0008-5472.CAN-08-0700. View

13.

ODowd G, Miller M, Orozco R, Veltri R . Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology. 2000; 55(4):553-9. DOI: 10.1016/s0090-4295(00)00447-7. View

14.

Harris R, Lohr K . Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137(11):917-29. DOI: 10.7326/0003-4819-137-11-200212030-00014. View

15.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

16.

Schuebel K, Chen W, Cope L, Glockner S, Suzuki H, Yi J . Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007; 3(9):1709-23. PMC: 1988850. DOI: 10.1371/journal.pgen.0030157. View

17.

Troyer D, Lucia M, de Bruine A, Mendez-Meza R, Baldewijns M, Dunscomb N . Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2717-22. DOI: 10.1158/1055-9965.EPI-09-0068. View

18.

Partin A, Brawer M, Bartsch G, Horninger W, Taneja S, Lepor H . Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol. 2003; 170(5):1787-91. DOI: 10.1097/01.ju.0000092695.55705.dd. View

19.

Van Neste L, Herman J, Otto G, Bigley J, Epstein J, Van Criekinge W . The epigenetic promise for prostate cancer diagnosis. Prostate. 2011; 72(11):1248-61. DOI: 10.1002/pros.22459. View

20.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View